Latest recommendation updates
ATAGI have not published any updated advice or recommendations since 7 July 2022.
Recent ATAGI considerations
On Wednesday 20 July 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation. As of 19 July 2022, over 61 million doses of COVID-19 vaccines have been administered in Australia.
ATAGI received a presentation on the World Health Organisation Technical Advisory Group on COVID-19 Vaccine Composition (WHO TAG-CO-VAC) current considerations in relation to emerging SARS-CoV-2 Variants of Concern (VOC) and the impact on the performance of COVID-19 vaccines.
Impact of COVID-19 vaccination on children aged 6 months to 4 years
ATAGI note on 19 July 2022 the Therapeutic Goods Administration provisionally approved the Moderna COVID-19 vaccine (SPIKEVAX) for use in children from 6 months of age.
ATAGI have continued reviewing data on the impact of SARS-CoV-2 infection on children aged 6 months to
ATAGI will provide advice to the Minister for Health on the use of COVID-19 vaccines in this age group in due course.
Ongoing review of adverse events and safety information
The TGA Fortnightly Report provides a detailed breakdown of adverse events following immunisation, including Australian rates of myocarditis and pericarditis.
